Takeno S, Hirano Y, Kitamura A, Sakai T
Department of Pharmacology, School of Pharmacy, Hokuriku University, Kanazawa, Japan.
Toxicol Appl Pharmacol. 1993 Aug;121(2):233-8. doi: 10.1006/taap.1993.1150.
This study was designed to evaluate the developmental toxicity of nitrazepam (NZ) in Sprague-Dawley rats and ICR mice and to determine the metabolic factors which modulate susceptibility to the developmental effects of NZ. Rats were treated orally with a single dose of NZ at 300 mg/kg on Day 12 of gestation. Mice received one dose of 300 mg/kg NZ via gavage between Days 9 and 14 of gestation. NZ administration resulted in a significant incidence of malformations in rats, while no evidence of teratogenic action was observed in mice. Pronounced species differences in the metabolism of NZ were observed. In rats, 7-acetylaminonitrazepam (AANZ) was detected as the major metabolite in plasma and embryos, whereas in mice, only small amounts of this product were found. The rate of N-acetylation of 7-aminonitrazepam (ANZ) to AANZ was 8.5-fold greater in rat liver cytosol than that in mouse liver cytosol. In contrast, the rate of deacetylation of AANZ to ANZ was 9-fold greater in mouse liver microsomes than that in rat liver microsomes. The developmental effects of authentic metabolites of NZ were studied in the two species. A single oral administration of 300 mg/kg ANZ to pregnant animals produced a significant incidence of malformations in rats, but not in mice. On the other hand, AANZ was teratogenic in both species. These results suggest that the difference in the susceptibility to NZ-induced teratogenicity between rats and mice may be related to differences in the levels of N-acetyltransferase and deacetylase, and that AANZ may be involved in the teratogenic mechanism.
本研究旨在评估硝西泮(NZ)对斯普拉格-道利大鼠和ICR小鼠的发育毒性,并确定调节对NZ发育效应易感性的代谢因素。在妊娠第12天,给大鼠口服单剂量300mg/kg的NZ。在妊娠第9至14天之间,通过灌胃给小鼠一剂300mg/kg的NZ。给予NZ后,大鼠出现明显的畸形发生率,而在小鼠中未观察到致畸作用的证据。观察到NZ代谢存在明显的物种差异。在大鼠中,7-乙酰氨基硝西泮(AANZ)被检测为血浆和胚胎中的主要代谢产物,而在小鼠中,仅发现少量该产物。大鼠肝细胞溶胶中7-氨基硝西泮(ANZ)向AANZ的N-乙酰化速率比小鼠肝细胞溶胶中的高8.5倍。相反,小鼠肝微粒体中AANZ向ANZ的脱乙酰化速率比大鼠肝微粒体中的高9倍。在这两个物种中研究了NZ真实代谢产物的发育效应。给怀孕动物单次口服300mg/kg的ANZ,大鼠出现明显的畸形发生率,而小鼠未出现。另一方面,AANZ在两个物种中均具有致畸性。这些结果表明,大鼠和小鼠对NZ诱导的致畸性易感性的差异可能与N-乙酰转移酶和脱乙酰酶水平的差异有关,并且AANZ可能参与致畸机制。